Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia.
about
From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemiaTherapy-related acute promyelocytic leukemiaThe cell biology of disease: Acute promyelocytic leukemia, arsenic, and PML bodiesHow animal models of leukaemias have already benefited patientsTargeting of leukemia-initiating cells in acute promyelocytic leukemiaThe clinical activity of arsenic trioxide, ascorbic acid, ifosfamide and prednisone combination therapy in patients with relapsed and refractory multiple myelomamiRNA-21 regulates arsenic-induced anti-leukemia activity in myelogenous cell lines.Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.Curing all patients with acute promyelocytic leukemia: are we there yet?Maintenance therapy with all-trans retinoic acid and arsenic trioxide improves relapse-free survival in adults with low- to intermediate-risk acute promyelocytic leukemia who have achieved complete remission after consolidation therapy.Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemiaThe effects of arsenic trioxide on DNA synthesis and genotoxicity in human colon cancer cellsInterference with Sin3 function induces epigenetic reprogramming and differentiation in breast cancer cells.ATO/ATRA/anthracycline-chemotherapy sequential consolidation achieves long-term efficacy in primary acute promyelocytic leukemia.Arsenic trioxide - An old drug rediscovered.Thioredoxin-1 inhibitor PX-12 induces human acute myeloid leukemia cell apoptosis and enhances the sensitivity of cells to arsenic trioxideDifferentiation of NUT midline carcinoma by epigenomic reprogramming.Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975-2008.Pathways of arsenic uptake and efflux.A Canadian consensus on the management of newly diagnosed and relapsed acute promyelocytic leukemia in adultsArsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710.Advances in treating acute myeloid leukemia.Catechins induced acute promyelocytic leukemia cell apoptosis and triggered PML-RARα oncoprotein degradation.As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia.Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemiaMultiple breast cancer cell-lines derived from a single tumor differ in their molecular characteristics and tumorigenic potentialDifferentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitorsArsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype.Molecular diagnostics in acute leukemias.Combination of arsenic and interferon-α inhibits expression of KSHV latent transcripts and synergistically improves survival of mice with primary effusion lymphomasIdentification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening.Phase 1 study of arsenic trioxide, high-dose cytarabine, and idarubicin to down-regulate constitutive signal transducer and activator of transcription 3 activity in patients aged <60 years with acute myeloid leukemiaIncidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxideTreatment of acute promyelocytic leukemia with single-agent arsenic trioxide.Newly diagnosed acute promyelocytic leukemiaHistory of acute promyelocytic leukemia: a tale of endless revolutionAddition of Arsenic Trioxide into Induction Regimens Could Not Accelerate Recovery of Abnormality of Coagulation and Fibrinolysis in Patients with Acute Promyelocytic LeukemiaMutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic TrioxideAll-Trans Retinoic Acid plus Arsenic Trioxide versus All-Trans Retinoic Acid plus Chemotherapy for Newly Diagnosed Acute Promyelocytic Leukemia: A Meta-Analysis.Future perspectives of Chinese medical formulae: chinmedomics as an effector.
P2860
Q24605527-4B437EF3-97EB-4656-9E28-9030337B02BFQ24629042-2515AC8A-09D4-43CE-8916-F1CDF06E9A56Q26853348-61DB47BF-AEA2-41CD-A035-BD555F2EA114Q26997702-0B6C18FC-E945-4497-9239-A339E7B5BB81Q28083807-254E8F5D-415E-4960-BA17-5F06B244D889Q33422349-7ED4177C-4232-465A-A394-6BEFFEE2ACF0Q33530333-1636D246-F6FB-448A-A2AF-91EAC5804AABQ33551142-5A95976E-F4DC-4B17-A4A1-A9757944811EQ33613426-AD6BFA81-0E9F-40B5-AEE5-F35CF1920ADBQ33631350-38AE0310-A63D-497C-AACB-34509A326D2DQ33710730-EAB534E0-176D-4CA6-A8B9-865ACD9E8731Q33965775-1AA28B29-0746-416C-8EF1-E45573639231Q33977987-626E70B3-80F5-4AB2-8A97-0388C9BBA3F2Q34046794-50FEA3C5-A238-433B-8905-2C08B427F7DDQ34054167-2F100EF5-71DC-49CE-A56B-D994CD772058Q34121354-58DD03DE-D464-4E82-B546-CE56CA35EFCDQ34174143-3D4553B6-107C-4117-8AC5-3138375AAB29Q34267886-0E8651E4-5B7C-4DEF-B645-21907B7CF439Q34304715-60743081-8456-421D-B398-61EA0EECF299Q34305899-E4430D52-AC75-4349-B72A-9FA2D7AD74C3Q34310859-D34D295B-2A4C-4F89-BC67-8A2B6DC87E1BQ34312351-AA77D303-6F67-4AE8-A984-A6EEB63A5F32Q34339982-99E7EAF4-51F5-43D6-8671-785A0516FB93Q34411016-C7EE54B4-A9B2-4015-9618-4D75AADFDD38Q34420787-4928EC44-2C39-4A2A-86B2-60DEDA325D50Q34571624-F3F72123-D113-4EAB-B6D6-A221CD96B315Q34658892-421C9070-9F5E-418A-9898-FBDC0BCD79F6Q34754867-830078AC-E04F-4A5D-9310-816C91732DAEQ35007333-C159D452-AEA3-4BEB-BD07-7AFEFE3CAAB1Q35046691-2314F703-1C8F-43FC-96D3-C2BBDDEE00A4Q35058617-61DD4559-3709-4A19-880B-2B9F78E7C1DDQ35085867-DFB28E14-6377-4DB0-951E-12535F5B68F2Q35563628-2C4EF779-7BE3-41D9-9D49-4E169C5469DDQ35640744-77DF0D9E-6E6A-4B13-BFCF-35C06536C114Q35640773-E8D90D28-D1E6-4087-8AE7-287CE0213278Q35640780-18E1CADA-C6DD-4A7B-9608-C3BF774DB2EBQ35904994-747DB025-2001-49D2-BDDB-A003646C677BQ35949253-A515BD5D-54FA-4073-BFD6-5346680F686BQ36070904-01B606D6-3782-4C1D-BFD0-597260E86E5EQ36089546-57D991AA-2B59-4312-B52F-715CC7D06CA3
P2860
Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Long-term efficacy and safety ...... acute promyelocytic leukemia.
@en
Long-term efficacy and safety ...... acute promyelocytic leukemia.
@nl
type
label
Long-term efficacy and safety ...... acute promyelocytic leukemia.
@en
Long-term efficacy and safety ...... acute promyelocytic leukemia.
@nl
prefLabel
Long-term efficacy and safety ...... acute promyelocytic leukemia.
@en
Long-term efficacy and safety ...... acute promyelocytic leukemia.
@nl
P2093
P2860
P356
P1476
Long-term efficacy and safety ...... acute promyelocytic leukemia.
@en
P2093
Arthur Zelent
Chuan-Feng Wu
Hui-Ping Sun
Jun-Min Li
Qiu-Sheng Chen
Sai-Juan Chen
P2860
P304
P356
10.1073/PNAS.0813280106
P407
P577
2009-02-18T00:00:00Z